Royalty Pharma Announces Dividend Increase
January 09 2023 - 8:30AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of
directors has declared a dividend for the first quarter of 2023 of
$0.20 per Class A share, reflecting a 5.3% increase in the
company’s quarterly dividend over the previous quarter’s dividend.
The dividend will be paid on March 15, 2023 to shareholders of
record at the close of business on February 16, 2023.
“We are pleased to once again announce an increase to our
dividend,” said Pablo Legorreta, Royalty Pharma’s founder and Chief
Executive Officer. “We are committed to returning capital to our
shareholders through our attractive dividend while retaining
financial flexibility to fund innovation. We continue to see
significant opportunities for value-enhancing growth as the demand
for capital in the biopharma ecosystem remains very strong.”
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie
and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s
Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT,
Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s
Trodelvy, and 12 development-stage product candidates. For more
information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024